Evidence map›Paper›PMID 29434190›Full record

ArticleCell death & disease2018

MiR-22 suppresses epithelial-mesenchymal transition in bladder cancer by inhibiting Snail and MAPK1/Slug/vimentin feedback loop.

Mingjie Xu, Jiangfeng Li, Xiao Wang, Shuai Meng, Jiaying Shen, Song Wang, Xin Xu, Bo Xie, Ben Liu, Liping Xie

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Article
  3. Expression levels of miRNA 22-5p and miRNA 337-5p in bladder cancer.The Indian journal of medical research · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Tumor-suppressive miR-29c binds to MAPK1 inhibiting the ERK/MAPK pathway in pancreatic cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mingjie XuDepartment of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jiangfeng LiDepartment of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Xiao WangDepartment of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Shuai MengDepartment of Urology, Zhejiang Provincial People's Hospital, Hangzhou, China.
Jiaying ShenProgram of Cancer Innovative Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Song WangDepartment of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Xin XuDepartment of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Bo XieDepartment of Urology, TongDe Hospital of Zhejiang Province, Hangzhou, China.
Ben LiuDepartment of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. drliuben@zju.edu.cn.
Liping XieDepartment of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. xielp@zju.edu.cn.
Zhejiang University · CNTongde Hospital of Zhejiang Province · CNZhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) have been validated to play prominent roles in the occurrence and development of bladder cancer (BCa). MiR-22 was previously reported to act as a tumor suppressor or oncomiRNA in various types of cancer. However, its accurate expression, function, and mechanism in BCa remain unclear. Here, we find that miR-22 is frequently downregulated in BCa tissues compared with adjacent non-cancerous tissues. Overexpression of miR-22 significantly inhibits proliferation, migration, and invasion of BCa cells both in vitro and in vivo. Importantly, miR-22 is found to suppress cell proliferation/apoptosis by directly targeting MAPK1 (mitogen-activated protein kinase 1, ERK2) and inhibit cell motility by targeting both MAPK1 and Snail. Further statistical analysis shows that low-expression of MAPK1 or Snail is an independent prognostic factor for a better overall survival in patients with BCa (n = 401). Importantly, we describe an important regenerative feedback loop among vimentin, Slug and MAPK1 in BCa cells. MAPK1-induced Slug expression upregulates vimentin. Vimentin in turn activates MAPK1. By inhibiting Snail and MAPK1/Slug/vimentin feedback loop, miR-22 suppresses epithelial-mesenchymal transition (EMT) of BCa cells in vitro as well as in vivo. Taken together, this study reveals that miR-22 is critical to the proliferation, apoptosis and EMT progression in BCa cells. Targeting the pathway described here may be a novel approach for inhibiting proliferation and metastasis of BCa.

Indexed as

Epithelial-Mesenchymal TransitionSignal TransductionAnimalsCell Line, TumorHumansMaleMice, Inbred BALB CMice, NudeMicroRNAsMitogen-Activated Protein Kinase 1Neoplasm ProteinsRNA, NeoplasmSnail Family Transcription FactorsUrinary Bladder NeoplasmsVimentinMAPK1 protein, humanMicroRNAsMIRN22 microRNA, humanMitogen-Activated Protein Kinase 1Neoplasm ProteinsRNA, NeoplasmSNAI1 protein, humanSnail Family Transcription FactorsVimentinVIM protein, human

Identifiers

PMID29434190
PMCPMC5833802
OpenAlexW2790082524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.